" class="no-js "lang="en-US"> Paul Radspinner - Medtech Alert
Friday, September 05, 2025
Paul Radspinner

Paul Radspinner

About Paul Radspinner

Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc. With Mr. Radspinner as President & CEO FluGen has raised over $40 million in capital and completed multiple human clinical trials with M2SR.

After completing his MBA at Northwestern University’s Kellogg Graduate School of Management he spent over 15 years in management roles overseeing international pharmaceutical operations, marketing and business development with Eli Lilly and Company. After his time at Lilly he managed the pharmaceuticals portfolio including Vitamin D analogs at the Wisconsin Alumni Research Foundation (WARF) for the University of Wisconsin-Madison. Mr. Radspinner entered the Madison biotech scene when he took on the role of Vice President of Business Development for Deltanoid Pharmaceuticals, Inc. and then started FluGen. In 2008 Mr. Radspinner was elected to the Board of Directors for BioForward, the Wisconsin state biotechnology organization where he served as President. Mr. Radspinner is a member of the Boards of Directors for Plumb Pharmaceuticals and Co-D Therapeutics.

Related Story

Naobios Delivers Flugen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials

June 22 2022

Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of […]

Naobios Manufactures FluGen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials

September 21 2021

Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of […]